TOPICS

2024/05/14
Precision Zebrafish Systems(PZS)による次世代ゼブラフィッシュ創薬

2024/05/14
Precision Zebrafish Systems(PZS)による次世代ゼブラフィッシュ創薬

2024/05/14
Precision Zebrafish Systems(PZS)による次世代ゼブラフィッシュ創薬

2024/05/09
ゼブラフィッシュ近交弱勢による品質劣化の対策戦略

2024/05/08
ゼブラフィッシュ創薬における最大の課題:近交弱勢

》oncocardiology of sorafenib

                     
2023/04/28

Oncocardiology is a subspecialty of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular complications caused by cancer therapies. Sorafenib is a tyrosine kinase inhibitor that is used to treat advanced hepatocellular carcinoma and renal cell carcinoma. However, sorafenib can also induce cardiotoxicity, such as hypertension, left ventricular dysfunction, heart failure and ischemia. The characterization of oncocardiology of sorafenib involves the identification of risk factors, biomarkers and imaging modalities that can help to monitor and manage the cardiac effects of this drug. Additionally, the characterization of oncocardiology of sorafenib requires the development of strategies to prevent or mitigate cardiotoxicity, such as dose adjustment, drug interruption or discontinuation, and the use of cardioprotective agents.

関連リンク

三重大学大学院医学系研究科システムズ薬理学

三重大学メディカルゼブラフィッシュ研究センター